Sai Parenterals Raises Rs 50 Crore for Global Expansion
Sai Parenterals Limited, an Indian pharmaceutical company, has raised Rs 50 crore in an equity funding round led by marquee investors including Samarsh Capital, Vyom Partners, and funds associated with Blue Lotus Capital.
Sai Parenterals operates across the pharmaceutical value chain, with a diverse product portfolio spanning injectables, oral solids and liquids, and topical preparations. The company operates five facilities in India, approved by international regulatory bodies such as TGA Australia, GCC, SAPRA, and WHO GMP. This funding will support its expansion into international markets and growth as a global pharmaceutical company.
The funding round also saw participation from Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, Devendra Chawla, Bhanwar Lal Chandak, Sreelekha Ganta, Padma Guntupalli, Vijay Gondi, Ideas And Journeys Private Limited, Bhautik Mukund Shah, and Nilesh Pravinchandra Doshi. Sai Parenterals has two strategic business verticals: Branded Export Formulations and Contract Development & Manufacturing Organization (CDMO) Services. Harikrishnan S, Managing Partner of Blue Lotus Capital, expressed confidence in the company's science-driven culture and scalable manufacturing platform. Anil Karusala, Managing Director of Sai Parenterals, stated that the funds will be used to acquire international assets and intellectual property, expand the product portfolio, and enhance manufacturing capabilities.
With this Rs 50 crore funding, Sai Parenterals aims to grow its presence in both domestic and key international markets, further solidifying its position as a global pharmaceutical company.
